P remenopausal women with normal estrogen levels rarely manifest coronary disease. In addition, the administration of exogenous estrogens to healthy postmenopausal women markedly reduces the incidence of coronary events. 1 However, the mechanisms underlying this benefit are unknown. The modest cholesterol-lowering effect of estrogens does not explain their substantial protective effects. 2 An alternative hypothesis is that estrogens protect against coronary heart disease through genomic mechanisms in the vascular bed. Estrogens inhibit the growth of vascular smooth muscle (VSM), which characterizes obstructive atherosclerotic lesions. 3, 4 Functional estrogen receptors (ERs) are present in VSM. 5 The structure of ER␣ was elucidated in 1987. 6 A second ER cDNA, designated ER␤, was cloned in l996. 7, 8 The 2 ERs have a similar affinity for 17␤-estradiol, and they bind to the same estrogen response elements (EREs). 9 However, ER␤ differs from ER␣ in 2 important functional domains. First, the N-terminus containing the AF-1 (activation function-1) activation domain of ER␤ has only 30% homology with that of ER␣. 7, 8 This domain is critical to the partial agonist properties of some antiestrogens, and it may be involved in tissue specificity. 10 Second, the hormone-binding domains (HBD) of ER␣ and ER␤ have only 53% homology. 7, 8 Why estrogens enhance the proliferation of breast or uterine cells but inhibit the proliferation of VSM cells is an enigma. One possible explanation for this heterogeneity of estrogen action is that the vascular bed expresses structurally and functionally different ERs than the breast or uterus. ER␣ is the predominant receptor in the breast and uterus. 11 However, because estrogens inhibit VSM proliferation in response to vascular injury in knockout mice that lack ER␣, 12 ER␣ is not essential to estrogen action in the vascular wall. Cynomolgus monkeys express both ER␣ and ER␤ mRNA in coronary artery and cultured aortic smooth muscle cells. 13 No information about the distribution of wild-type ERs in human VSM exists.
This study had 2 goals: to describe the relative expression of ER␣ and ER␤ transcripts in VSM and to elucidate whether differences exist in the transcriptional activation and function of ER␣ and ER␤.
Methods

RNA Isolation and RT-PCR
VSM tissue from the human coronary artery, iliac artery, aorta, or saphenous vein was cultured for 72 hours and then frozen at Ϫ80°C, as described previously. 14 Total RNA was isolated with TriReagent (Sigma).
RNA (0.5 to 1.0 g) was heated to 70°C for 5 minutes, and 125 U of MuLV RT was added. Using the random hexamer oligo primer supplied in a GeneAmp RNA PCR kit (Perkin Elmer), an RT reaction was performed at 42°C for 60 minutes. After dilution of the RT cDNA product, PCR was performed with the following thermal cycles: 1 cycle at 94°C for 1 minute, followed by 35 cycles at 94°C for 15 s, 55°C for 25 s, and 72°C for 30 s, and 1 final extension cycle at 72°C for 7 minutes. Products were resolved on an 8% polyacrylamide gel in 1ϫ Tris-borate/EDTA buffer (0.09 mol/L Tris-borate and 0.002 mol/L EDTA, pH 8.0).
Primers
To simultaneously amplify ER␣ and ER␤ in the same PCR reaction, oligonucleotide primers were designed for PCR amplification of specific DNA fragments contained in both ER␣ and ER␤ (Figure 1 ). The forward primer sequence, ERF2, was AAGAGCTGCCAGGC-CTGCCG, and the reverse primer sequence, ERR1, was GCCCAG-CTGATCATGTGAACCA. There was one mismatch in ERR1 for both ER␤ (AT mismatch) and ER␣ (AG mismatch). The primer ERR1 had similar stability on both templates. The primer pair ERF2 and ERR1 generated a 382-bp fragment for ER␣ and a 346-bp fragment for ER␤. These primers were tested on ER␣ and ER␤ cDNA plasmid clones to ensure that they generated the specific products targeted, with equivalent efficiency under the same amplification conditions. Primers specific for ER␣ or ER␤ only, but capable of distinguishing the wild-type from the variant forms of each, were also designed. The ER␣-specific primers, a forward primer ERAF1 (GTCTC-CGAGCCCGCTGATGCTACTGCAC) and a reverse primer ERAR1 (CGGATGCCCCTCCACGGCTAGTGG), generated a 1372-bp fragment. The ER␤-specific primers, forward primer ERBF1 (CGTGATGGAGGACTTGCACCCGCGAAGCAC) and reverse primer ERBR1 (TCCCTGGTGTGAAGCAAGTATCG-CTAGAACA), generated a 1212-bp fragment.
Plasmids
Wild-type human ER␣ expression vector was provided by Dr Pierre Chambon (Strasbourg, France). The human ER␤ Bluescript KS construct was provided by Drs Eva Enmark and Jan-Ake Gustafsson (Stockholm, Sweden). The 1460-bp ER␤ insert was recloned into the pSG5 expression vector (Stratagene) to generate pSG5-hER. The reporter plasmids were VIT-tk-CAT 15 and ERE 2 -TATA tk -CAT. 16 
Transfection and Reporter Assays
Transfection experiments used 10 ng of human ER␣ expression vector or ER␤ plasmid, 2 g of ERE 2 -TATA tk -CAT or VIT-tk-CAT reporter, 3 g of the ␤-galactosidase expression plasmid pCH-110 (Amersham Pharmacia Biotechnology) to correct for transfection efficiency, and 15 g of Bluescribe carrier plasmid, for a total of 20 g of DNA/plate. 16 Cells were treated for 24 hours with 10 nmol/L 17␤-estradiol and/or 100 nmol/L tamoxifen or ICI 182,780 (ICI Pharmaceuticals). Cell lysates were analyzed for CAT activity, as previously described, 16 with chloramphenicol acetylation measured by thin-layer chromatography and quantified by phosphorimaging (Molecular Dynamics).
Statistical Analysis
Statistical analysis was performed with SAS software (SAS Institute). The 2-tailed significance level was 0.05. Independent groups were compared using the unpaired t test, and dose response was assessed by linear regression.
Results
Distribution of ER␣ and ER␤ Transcripts in Human VSM
To investigate the relative levels of ER␣ and ER␤ expression in human VSM, we designed primers that coamplified different transcript fragment lengths for each subtype in the same polymerase chain reaction (PCR). The combined ER␣/␤ primer set (ERF2/ERR1; see Methods for a complete description) amplifies both a region of the cDNA encoding the DNA binding domain (DBD) and the hinge region of the 2 receptors that has a gap in ER␤ when compared with the ER␣ sequence ( Figure 1A) . A 382-bp product was generated from the cDNA encoding ER␣, and a 346-bp product from ER␣ to ER␤ ratios: wild-type (Wt) ER␤ expression predominates. A, Total RNA in VSM from 12 patients was reverse-transcribed into cDNA. RT-PCR using combined ER␣/ ER␤ primer set was performed on cDNA, and reaction products were loaded on an 8% polyacrylamide gel. Human ER␣ expression vector and ER␤ plasmids were positive controls, and reaction mixtures lacking RT were negative controls (not shown). The 382-bp fragments amplified from ER␣ and the 346-bp fragments amplified from ER␤ are present in all samples, although the ER␤ band in lane 6 is extremely faint. Lanes 3 through 6 were samples from male subjects, and lanes 1, 2, and 7 through 12 were samples from female subjects. B, Independent primers for ER␣ or ER␤ were used to amplify the cDNA reversetranscribed from the RNA of a female patient. Reaction products were resolved on an agarose gel and stained with ethidium bromide. The 1372-bp ER␣ and 1212-bp ER␤ amplified DNA fragments expected from the wild-type receptors are denoted by the open arrows, and the shorter splice variants by solid arrows. A single ER␤ splice variant and several ER␣ splice variants are present.
the cDNA encoding ER␤. Equal efficiency of the PCR amplification reactions was confirmed using control plasmid DNA containing the recombinant cDNA of ER␣ or ER␤ in molar ratios of 1:3 ( Figure 1B , lane 1), 1:1 (lane 2), and 1:2 (lane 3). Therefore, it was possible to simultaneously measure the relative reverse-transcriptase (RT) PCR product amount for each ER subtype, despite the exponential nature of PCR and the minimal variations in template sequences and reaction efficiencies.
ER␣ and ER␤ RT-PCR products (determined using the combined ER␣/␤ primer sets) in VSM from 12 patients are shown in Figure 2A . Although both ER␣ and ER␤ transcripts were present in all samples, some subsets expressed considerably more ER␤ than ER␣. The values of ER␤, expressed as a percentage of total ER, in samples of VSM from 8 male and 12 female subjects, are shown in the Table. ER␤ was more prevalent in the VSM from female subjects (67Ϯ12%) than in those from male subjects (51Ϯ15%; Pϭ0.02). ER␤ did not correlate with age in either sex.
To determine if exposure to estrogens could alter the ER␣/ER␤ ratio, samples of VSM from 8 male and 12 female patients were treated for 72 hours with 17␤-estradiol or vehicle. No consistent differences existed in the subtype ratios between estrogen-treated sets and controls. Studies of samples from 3 patients found no differences in ER ratios between tissue immediately frozen when obtained and tissue incubated for 72 hours in medium (data not shown).
The combined primer set quantifies relative amounts of each subtype, but it cannot discriminate between wild-type, full-length ER␣ or ER␤ and HBD deletion variants of these subtypes. ER␣ variants are common in VSM. 14 Therefore, we also used primers designed to amplify longer lengths of either ER␣ or ER␤ specifically ( Figure 1A ). These included ERAF1/ERAR1 for ER␣ and ERBF1/ERBR1 for ER␤, which included the N-terminus, DBD, hinge region, and HBD ( Figure 2B) . The specific primers were tested using plasmid DNA containing ER␣ or ER␤ to confirm that the PCR generated full-length products (data not shown). The major transcript encoding ER␤ of the sample shown in Figure 2B is full-length (open arrow), although a small band representing a lower molecular weight variant (solid arrow) can be discerned. However, the ER␣ transcripts are present predominantly as variant forms (solid arrows): there is little fulllength, wild-type ER␣ present (open arrow). Similar results were obtained in the other 19 samples of VSM (data not shown). Therefore, the results with the combined ER␣/ER␤ primer set underestimate the ratio of wild-type ER␤ to wild-type ER␣ transcripts.
Transcription by ER␣ and ER␤: Promoter and Ligand Specificity
To examine differences in promoter specificity between ER␣ and ER␤, ER-negative HeLa cells were cotransfected with either the ERE 2-TATA tk -CAT ( Figure 3A) or vitellogenin (VIT-tk-CAT) ( Figure 3B ) promoter/reporter constructs, as well as increasing concentrations (1 to 100 ng) of ER␣ or ER␤ expression vectors. The cells were treated with vehicle or 10 nmol/L 17␤-estradiol. The chloramphenicol transferase (CAT) transcription driven by each promoter was measured. Substantial estradiol-induced transcription occurred in cells with low levels of ER␣; however, as the receptor concentration increased, transcription decreased due to a phenomenon called "self-squelching." The mechanism underlying selfsquelching is unknown, but a similar effect of the progesterone receptor A-isoform requires an intact HBD. 17 Unlike ER␣, ER␤ had no transcriptional activity with ERE 2 -TATA tk -CAT ( Figure 3A) . With VIT-tk-CAT, estradiol induced similar transcriptional activity in ER␤ and ER␣ at low concentrations (1 and 5 ng cDNA; Figure 3B ). However, at higher receptor concentrations, because ER␤ did not selfsquelch, it was a more potent transactivator than ER␣. The ERE 2 -TATA tk -CAT promoter construct contains 2 consecutive, synthetic EREs upstream of a minimal thymidine kinase promoter linked to the CAT gene. 16 The VIT-tk-CAT promoter contains 2 repeats of the ERE found in the vitellogenin A1 gene promoter. 15 Differences in the EREs and flanking sequences probably account for the differences in promoter recognition by the 2 ERs. Specifically, the VIT-tk-CAT promoter has several potential AP-1 sites that could modulate transcriptional activation by the 2 ERs. 18 Such differences in specific gene transcription between the 2 receptors may underlie the variation in responses to 17␤-estradiol observed in different tissues, including VSM. To further analyze possible differences in the transcriptional activities of ER␣ and ER␤, we studied the differential effects of antiestrogens. Some antiestrogens possess partial agonist activity (ie, tamoxifen), and others are pure antagonists (ie, ICI 182,780). HeLa cells were cotransfected with ER␣ or ER␤ and with the reporters ERE 2 -TATA tk -CAT ( Figure 4A ) or VIT-tk-CAT ( Figure 4B ). The transfected cells were treated with 17␤-estradiol, tamoxifen, or ICI 182,780, either alone or in combination. Compared with Figure 3 . ER␤ has different promoter transactivation effects than ER␣, and it does not self-squelch. HeLa cells were cotransfected with expression vectors (1 to 100 ng) encoding ER␣ or ER␤ and either ERE 2 -TATA tk -CAT (A) or VIT-tk-CAT (B) reporters. Cells were treated with 10 nmol/L 17␤-estradiol, and CAT activity was measured by thin-layer chromatography using cell lysates that were normalized to ␤-galactosidase activity. An empty vector lacking ER was used to evaluate background transcription, which was subtracted. 17␤-estradiol, tamoxifen is a partial agonist on the ERE 2 -TATA tk -CAT reporter when bound to ER␣; under these conditions, tamoxifen did not suppress the agonist effects of 17␤-estradiol ( Figure 4A ). ICI 182,780 had no agonist effect on this promoter and strongly suppressed the transcription induced by 17␤-estradiol. ER␤ did not induce the transcription of ERE 2 -TATA tk -CAT with any ligand ( Figure 4A) .
Tamoxifen is also an agonist in the presence of ER␣ on the VIT-tk-CAT reporter ( Figure 4B ). Again, ICI 182,780 is a pure antagonist. When bound to ER␤ with VIT-tk-CAT, tamoxifen lacked partial agonist activity and, unlike ICI 182,780, it did not suppress the agonist effects of 17␤-estradiol.
L7/SPA is a novel transcriptional coactivator that enhances the partial agonist effect of tamoxifen but has no effect on transactivation by estrogens or pure antagonists. 19 To determine whether any ER␤-mediated latent partial agonist activity by tamoxifen could be exposed, this antiestrogen was tested on both ER subtypes in the presence of an L7/SPA expression vector using the VIT-tk-CAT reporter ( Figure 5 ). Coexpression of L7/SPA increased the partial agonist effects of tamoxifen on ER␣ to levels that exceeded those obtained with 17␤-estradiol. However, even in the presence of L7/ SPA, no agonist effects of tamoxifen were detectable in cells transfected with ER␤ constructs. Thus, a fundamental difference exists in the 2 ERs with respect to the actions of antiestrogens.
Effect of ER␤ on Transcriptional Effects of ER␣
Because ER␣ and ER␤ are coexpressed in VSM, it is important to determine whether the presence of one ER subtype can modify the transcriptional effects of the other. We examined the effect of ER␤ on ER␣-controlled transcription of the VIT-tk-CAT reporter in cells treated with tamoxifen ( Figure 6 ). A 5-fold molar excess of ER␤ substantially reduced the agonist effect of tamoxifen on ER␣ (Pϭ0.005 for linear dose response and Pϭ0.02 for dose of 0 versus 2.5). Therefore, at least one transcriptional effect of ER␣ can be inhibited by the presence of ER␤.
Discussion
Considerable clinical information has supported the notion that estrogens protect against atherosclerosis, particularly coronary artery disease. Atherosclerotic-mediated events are rare in premenopausal women, and exogenous estrogen reduces their incidence in healthy postmenopausal women. 1 However, in the Heart and Estrogen-progestin Replacement Study (HERS), 20 a randomized, placebo-controlled protocol in postmenopausal women with preexisting coronary artery disease, treatment with 0.625 mg of conjugated equine estrogens with 2.5 mg of medroxyprogesterone acetate failed to reduce coronary events and increased thromboembolic events. Although it is possible that the large body of previous evidence showing that estrogens protect the vascular bed is incorrect, other explanations for the findings in the HERS study deserve consideration. (1) In light of the increase in thromboembolic events in the HERS study, an increased tendency to thrombosis due to the hormone therapy may have offset the beneficial effects in the vascular wall. (2) Evidence from animal studies indicates that concomitant administration of the progestin medroxyprogesterone acetate may have adverse vascular effects that oppose the protective effects of estrogens. 21, 22 Although the relationship between estrogens and vascular disease is poorly understood, evidence exists that estrogens have genomic effects on the vascular wall, which is probably mediated through ERs. These effects include the inhibition of VSM growth and migration in vitro and the inhibition of arterial intimal hyperplasia in vivo. 3, 4 Without dietary manipulation or vascular trauma, ovarian ablation in sheep induces aortic intimal hyperplasia, which can be prevented by the administration of an estrogen. 23 A seeming paradox of estrogenic effects is the observation of growth inhibition in the vascular bed but growth stimulation in other target organs, such as the breast and uterus. Our demonstration that the newly discovered ER␤ subtype is the most prevalent receptor mRNA in human VSM offers a possible explanation for the important differences in the effects of estrogens on the vascular bed compared with other organs. We offer evidence that ER␤ differs in its transcriptional activation and effects from ER␣, which is the most prevalent receptor in the breast and uterus. 11 We propose that the physiological effects of estrogens or antiestrogens in a tissue depend to a considerable extent on the type of ER expressed in that tissue.
ER␤ is the Prevalent Wild-Type ER mRNA in Human VSM
Because reliable monoclonal antibodies for human ER␤ are not commercially available, we used RT-PCR to quantify transcript expression for both ER␣ and ER␤ in human VSM. Our method allows the cDNA encoding each subtype to be amplified in the same reaction tube. Because the amplified products differ in size, they can be distinguished from one another on electrophoretic gels, and the relative percentage of each ER subtype in a sample can be quantified. Because this method cannot distinguish between wild-type and exondeletion variants of ER␣ and ER␤, we also performed separate PCR reactions using primers that recognized longer transcripts specific for either ER␣ or ER␤.
We demonstrated that although both ER␤ and ER␣ mRNA were present in all 20 subjects we studied, the more prevalent wild-type receptor mRNA was ER␤. In women, ER␤ was present in higher quantities in most samples, and in men, ER␤ and ER␣ were present in approximately equal quantities. Qualitative analysis of the mRNAs with specific primers demonstrated that ER␤ was encoded primarily by full-length transcripts, but ER␣ transcripts included substantial amounts of putative exon-deletion variants.
The importance of variant ER messages due to exon deletions is unclear. In cells transfected with variants of ER␣, stimulation with estrogens could result in anomalous transcriptional activities that dominantly inhibit or enhance the effects of wild-type ER␣. 14, 24, 25 There has been no confirmation that the ER␣ variant transcripts are translated into proteins in vivo. Thus, ER␣ exon-deletion variants may have no physiological effects. If so, the wild-type receptors would determine the estrogenic effects in VSM, and ER␤ would be the major receptor subtype mediating transcription.
Potential Influence of Differences in Structure of ER␣ and ER␤ on Function
Human ER␤ differs significantly from ER␣ at the N-terminus (including the AF-1 region), the hinge region, and the HBD (including differences in the AF-2 region and F domain at the far C-terminus; Figure 1 ). Although the functional domains of ER␤ have not yet been delineated, these structural differences probably account for differences in transcriptional activities. The AF-1 region of ER␣ is responsible for the partial agonist effects of tamoxifen, 10,26 and we found that tamoxifen lacks partial agonist activity on ER␤. Structural differences between the 2 subtypes in the AF-2 region and the F domain may also contribute to the differing effects of antiestrogens on the 2 receptors. In crystallographic analyses, the F domain generates an ␣-helix (helix 12), whose appropriate folding over the surface of the ligand-activated HBD is critical in imparting agonist versus antagonist information to the transcriptional machinery. 27, 28 The amino acid composition of the ER␤ F domain differs considerably from that of ER␣. 7, 8 Our data also allowed us to deduce important functional information about the hinge region between the DBD and HBD. We recently isolated a transcriptional coactivator (termed L7/SPA) that binds to the hinge region of ER␣ and enhances the agonist activity of antiestrogens, such as tamoxifen. 19 Thus, the hinge region may be an important site for protein-protein interactions. Because tamoxifen-occupied ER␤ is not influenced by L7/SPA (Figure 5 ), the ER␤ hinge region functions differently from that of ER␣, which has only 19% homology with ER␤.
Possible Functional Significance of the Prevalence of ER␤ in VSM
Although low levels of wild-type ER␣ induce strong estrogenic responses, self-squelching limits transcriptional activity at higher receptor levels. Because ER␤ does not self-squelch, at high concentrations, ER␤ is a more potent transactivator than ER␣. Cotransfection of ER␤ did not suppress estradiolinduced, ER␣-dependent transcription (data not shown).
However, tamoxifen bound to ER␤ suppressed the agonist effects of tamoxifen-occupied ER␣. Complicating any analysis is the observation that the inhibitory potency of antagonists and their agonist effects are dependent on promoter context and cell-type specificity. 29 We found that with ER␣, tamoxifen had partial agonist effects on the ERE 2 -TATA tk -CAT promoter but not on the VIT-tk-CAT promoter. Tamoxifen-occupied ER␤ lacks agonist effects on both promoters. Nevertheless, tamoxifen-occupied ER␤ can have agonist effects on some promoters containing AP-1 sites. 18 
Potential Clinical Importance of ER␤ Activation in VSM
Inhibition by estrogens of VSM growth in vitro can be prevented by the antiestrogen ICI 182,780 and by actinomycin D, an inhibitor of transcription. 4 This observation supports the hypothesis that the effects of estrogens in VSM are primarily mediated through classic ER-dependent transcriptional mechanisms. Interestingly, in ER␣-deficient mice (ERKO), estrogens inhibit VSM proliferation in response to vascular injury. 12 Because ER␤ is expressed in the vasculature of these mice, this receptor subtype seems to be sufficient for mediating the antiproliferative effects of estrogens.
If, as we propose, the predominant ER in a tissue determines the local physiological effects of estrogens, the clinical implications of the high prevalence of ER␤ in the vascular bed are considerable. The differential effects of ER␤ activation in the vascular bed offer an attractive hypothesis to explain why estrogens are inhibitory in this tissue but stimulatory in others.
